Docoh
Loading...

TECH Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Company profile

Ticker
TECH
Exchange
CEO
Charles Kummeth
Employees
Incorporated
Location
Fiscal year end
Former names
TECHNE CORP /MN/
SEC CIK
IRS number
411427402

TECH stock data

(
)

Calendar

7 May 21
18 May 21
30 Jun 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jun 20 Jun 19 Jun 18 Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Bio-Techne earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 May 21 Kelderman Kim Common Stock Payment of exercise Dispose F No No 427.49 856 365.93K 1,656
1 May 21 Kelderman Kim Common Stock Option exercise Aquire M No No 0 1,667 0 2,512
1 May 21 Kelderman Kim RSU Common Stock Option exercise Dispose M No No 0 1,667 0 0
1 Mar 21 Furlow Brenda S. Stock Options Common Stock Grant Aquire A No No 372.44 10,997 4.1M 10,997
16 Feb 21 Kummeth Charles R. Common Stock Payment of exercise Dispose F No No 411 17,428 7.16M 158,841
16 Feb 21 Kummeth Charles R. Common Stock Option exercise Aquire M No No 94.35 30,000 2.83M 176,269
16 Feb 21 Kummeth Charles R. Stock Options Common Stock Option exercise Dispose M No No 94.35 30,000 2.83M 36,849
12 Feb 21 Furlow Brenda S. Common Stock Sell Dispose S No No 399.1165 3,326 1.33M 6,124
12 Feb 21 Furlow Brenda S. Common Stock Sell Dispose S No No 398.3954 6,674 2.66M 9,450
12 Feb 21 Furlow Brenda S. Common Stock Option exercise Aquire M No No 106.59 10,000 1.07M 16,124

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Competition
Genomic HealthNanostringQuanterix
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: approved, Asuragen, cope, educating, January, outflow, sponsoring, vaccinated, vaccination, vaccine, widely

Patents

APP
Utility
Hybridoma Clones, Monoclonal Antibodies to VSIG-4, and Methods of Making and Using
25 Mar 21
Described herein are monoclonal antibodies that bind to VSIG-4 including antibodies that block the binding of VSIG-4 to SIGLEC-7, compositions including the monoclonal antibodies, and methods of making and using those antibodies and compositions.
APP
Utility
Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
4 Feb 21
Methods of detecting multiple nucleic acid targets in single cells through indirect capture of labels to the nucleic acids are provided.
APP
Utility
Methods to Further Enhance Signal Amplification for the In Situ Detection of Nucleic Acids
4 Feb 21
The present invention relates to detection of nucleic acids and provides a composition comprising a Signal Generating Complex, wherein the composition comprises: (A) a pair of target probes (TPs), wherein a first TP of the pair of TPs comprises a nucleic acid sequence comprising two segments; (B) a pair of base PPAs comprising the first and second base PPAs, wherein the first base PPA comprises a nucleic acid sequence comprising three segments; (C) a set of extension PPAs comprising the first and second extension PPAs, wherein the first extension PPA comprises a nucleic acid sequence comprising two segments; (D) a plurality of pre-amplifiers (PAs), wherein the PAs comprise a nucleic acid sequence comprising three segments; (E) a plurality of amplifiers (AMPs), wherein the AMPs comprise a nucleic acid sequence comprising two segments; and (F) a plurality of label probes (LPs), wherein the LPs comprise a nucleic acid sequence comprising two segments.
GRANT
Utility
Methods and kits for assaying endoglycosidase activity
12 Jan 21
A method for assaying endoglycosidase activity includes providing a proteoglycan having a glycosaminoglycan chain with a non-reducing end; treating the proteoglycan with a glycosyltransferase to incorporate a carbohydrate into the non-reducing end of the glycosaminoglycan chain, wherein the carbohydrate includes a click chemistry moiety; adding a label to the proteoglycan, wherein the label includes a click chemistry moiety that reacts to the click chemistry moiety of the carbohydrate such that the label attaches to the carbohydrate to form a labeled proteoglycan; immobilizing the labeled proteoglycan on a multi-well plate, wherein the multi-well plate includes a specific anti-proteoglycan antibody for binding the labeled proteoglycan; treating the labeled proteoglycan with an endoglycosidase specific to the glycosaminoglycan chain; and detecting the labeled proteoglycan.
APP
Utility
Methods of Detecting Nucleic Acids In Individual Cells and of Identifying Rare Cells from Large Heterogeneous Cell Populations
30 Dec 20
Methods of detecting multiple nucleic acid targets in single cells through indirect capture of labels to the nucleic acids are provided.